High Cytoplasmic CXCR4 Expression Predicts Prolonged Survival in Triple-Negative Breast Cancer Patients Treated with Adjuvant Chemotherapy
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Chemokine receptor CXC chemokine receptor type 4 (CXCR4) and its ligand CXC motif chemokine 12 (CXCL12; stromal cell-derived factor-1) are implicated in tumor growth, metastasis, and tumor cell-microenvironment interaction. A number of studies have reported that increased CXCR4 expression is associated with worse prognosis in triple-negative breast cancer (TNBC), but its prognostic significance has not been studied in TNBC patients treated with adjuvant chemotherapy. Methods: Two hundred eighty-three TNBC patients who received adjuvant chemotherapy were retrospectively analyzed. Tissue microarray was constructed from formalinfixed, paraffin-embedded tumor tissue and immunohistochemistry for CXCR4 and CXCL12 was performed. Expression of each marker was compared with clinicopathologic characteristics and outcome. Results: High cytoplasmic CXCR4 expression was associated with younger age (p = .008), higher histologic grade (p = .007) and lower pathologic stage (p = .045), while high CXCL12 expression was related to larger tumor size (p = .045), positive lymph node metastasis (p = .005), and higher pathologic stage (p = .017). The patients with high cytoplasmic CXCR4 experienced lower distant recurrence (p = .006) and better recurrence-free survival (RFS) (log-rank p = .020) after adjuvant chemotherapy. Cytoplasmic CXCR4 expression remained an independent factor of distant recurrence (p = .019) and RFS (p = .038) after multivariate analysis. Conclusions: High cytoplasmic CXCR4 expression was associated with lower distant recurrence and better RFS in TNBC patients treated with adjuvant chemotherapy. This is the first study to correlate high CXCR4 expression to better TNBC prognosis, and the underlying mechanism needs to be elucidated in further studies.
Abstract
Background: Chemokine receptor CXC chemokine receptor type 4 (CXCR4) and its ligand CXC motif chemokine 12 (CXCL12; stromal cell-derived factor-1) are implicated in tumor growth, metastasis, and tumor cell-microenvironment interaction. A number of studies have reported that increased CXCR4 expression is associated with worse prognosis in triple-negative breast cancer (TNBC), but its prognostic significance has not been studied in TNBC patients treated with adjuvant chemotherapy. Methods: Two hundred eighty-three TNBC patients who received adjuvant chemotherapy were retrospectively analyzed. Tissue microarray was constructed from formalinfixed, paraffin-embedded tumor tissue and immunohistochemistry for CXCR4 and CXCL12 was performed. Expression of each marker was compared with clinicopathologic characteristics and outcome. Results: High cytoplasmic CXCR4 expression was associated with younger age (p = .008), higher histologic grade (p = .007) and lower pathologic stage (p = .045), while high CXCL12 expression was related to larger tumor size (p = .045), positive lymph node metastasis (p = .005), and higher pathologic stage (p = .017). The patients with high cytoplasmic CXCR4 experienced lower distant recurrence (p = .006) and better recurrence-free survival (RFS) (log-rank p = .020) after adjuvant chemotherapy. Cytoplasmic CXCR4 expression remained an independent factor of distant recurrence (p = .019) and RFS (p = .038) after multivariate analysis. Conclusions: High cytoplasmic CXCR4 expression was associated with lower distant recurrence and better RFS in TNBC patients treated with adjuvant chemotherapy. This is the first study to correlate high CXCR4 expression to better TNBC prognosis, and the underlying mechanism needs to be elucidated in further studies.
참고문헌 (32)
- Boyle P, "Triple-negative breast cancer: epidemiological considerations and recommendations", Ann Oncol, 23(Suppl 6), pp.vi7~vi12 (2012)
- Bianchini G, "Triplenegative breast cancer: challenges and opportunities of a heterogeneous disease", Nat Rev Clin Oncol, 13, pp.674~690 (2016)
- Balkwill F, "Cancer and the chemokine network", Nat Rev Cancer, 4, pp.540~550 (2004)
- Nagasawa T, "Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF", SDF-1, 1996, pp.382, 635~638
- Baggiolini M, "Chemokines and leukocyte traffic", Nature, 392, pp.565~568 (1998)
- Zou YR, "Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development", Nature, 393, pp.595~599 (1998)
- Domanska UM, "A review on CXCR4", CXCL12 axis in oncology: no place to hide, 2013, pp.49, 219~230
- Orimo A, "Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1", CXCL12 secretion, 2005, pp.121, 335~348
- Muller A, "Involvement of chemokine receptors in breast cancer metastasis", Nature, 410, pp.50~56 (2001)
- Liu Y, "orrelation effect of EGFR and CXCR4 and CCR7 chemokine receptors in predicting breast cancer metastasis and prognosis", J Exp Clin Cancer Res, 29, pp.16~ (2010)
- Zhang Z, "Expression of CXCR4 and breast cancer prognosis: a systematic review and meta-analysis", BMC Cancer, 14, pp.49~ (2014)
- Smith MC, "CXCR4 regulates growth of both primary and metastatic breast cancer", Cancer Res, 64, pp.8604~8612 (2004)
- Huang EH, "A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer", J Surg Res, 155, pp.231~236 (2009)
- Chu QD, "High chemokine receptor CXCR4 level in triple negative breast cancer specimens predicts poor clinical outcome", J Surg Res, 159, pp.689~695 (2010)
- Yu S, "High level of CXCR4 in triplenegative breast cancer specimens associated with a poor clinical outcome", Acta Med Okayama, 67, pp.369~375 (2013)
- Chen HW, "Cytoplasmic CXCR4 high-expression exhibits distinct poor clinicopathological characteristics and predicts poor prognosis in triple-negative breast cancer", Curr Mol Med, 13, pp.410~416 (2013)
- Hammond ME, "American Society of Clinical Oncology", College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer, 2010, pp.28, 2784~2795
- Wolff AC, "Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology", College of American Pathologists clinical practice guideline update, 2013, pp.31, 3997~4013
- Elston CW, "Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up", Histopathology, 19, pp.403~410 (1991)
- Hudis CA, "Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system", J Clin Oncol, 25, pp.2127~2132 (2007)
- Guo F, "CXCL12", CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks, 2016, pp.35, 816~826
- Haribabu B, "Regulation of human chemokine receptors CXCR4. Role of phosphorylation in desensitization and internalization", J Biol Chem, 272, pp.28726~28731 (1997)
- Salvucci O, "The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study", Breast Cancer Res Treat, 97, pp.275~283 (2006)
- Hassan S, "The influence of tumor-host interactions in the stromal cell-derived factor-1", CXCR4 ligand, Am J Pathol, pp.2009, 175[DOI]
- Alda Losi Guembarovski, "CXCL12 chemokine and CXCR4 receptor: association with susceptibility and prognostic markers in triple negative breast cancer", Molecular Biology Reports, 45(5), pp.741~750 (2018), Springer Nature[DOI]
- Kobayashi T, "Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis", Breast Cancer Res Treat, 123, pp.733~745 (2010)
- Mirisola V, "CXCL12", SDF1 expression by breast cancers is an independent prognostic marker of diseasefree and overall survival, 2009, pp.45, 2579~2587
- Yan M, "Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers", Breast Cancer Res, 13, pp.R47~ (2011)
- Kang H, "Stromal cell derived factor-1: its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer", Breast Cancer Res, 7, pp.R402~R410 (2005)
- Samarendra H, "A meta-analysis of CXCL12 expression for cancer prognosis", Br J Cancer, 117, pp.124~135 (2017)
- Lefort S, "CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients", Oncogene, 36, pp.1211~1222 (2017)
- Lebert JM, "Advances in the systemic treatment of triple-negative breast cancer", Curr Oncol, 25(Suppl 1), pp.S142~S150 (2018)